HBV-specific antigen peptide- and HepG2 lysate-activated dendritic cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HBV-specific antigen peptide- and HepG2 lysate-activated dendritic cells, covering 2020-10-30 to 2020-10-30. Get the full timeline:
Most recent: Clinical Trial Update: A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT) [Phase 1, Phase 2]